摘要
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy. A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy. In the last few years, the use of immune checkpoint inhibitors (ICIs), such as those targeting the PD-1/PD-L1 axis and CTLA-4, has dramatically changed the cancer treatment landscape. ICIs have been integrated into the standard of care for patients with different kinds of recurrent or metastatic cancers (Chan et al., 2019Chan T.A. Yarchoan M. Jaffee E. Swanton C. Quezada S.A. Stenzinger A. Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.Ann. Oncol. 2019; 30: 44-56Abstract Full Text Full Text PDF PubMed Scopus (490) Google Scholar). However, the development of immunotherapy biomarkers still suffers from significant limitations, namely their lack of sufficient predictive ability in specific disease entities, as well as their insufficient negative predictive value (Samstein et al., 2019Samstein R.M. Lee C.H. Shoushtari A.N. Hellmann M.D. Shen R. Janjigian Y.Y. Barron D.A. Zehir A. Jordan E.J. Omuro A. et al.Tumor mutational load predicts survival after immunotherapy across multiple cancer types.Nat. Genet. 2019; 51: 202-206Crossref PubMed Scopus (941) Google Scholar). From a conceptual point of view, immunotherapy biomarkers may be classified into those that positively identify responders (positive predictor) and those that are able to detect non-responders (negative predictors). While the former class has already entered clinics, promising candidates of the latter group are still under investigation. Biologically, such biomarkers can be characterized further as either interrogating the specific makeup of the tumor (TMB, neoantigens) or the status of effector compartments (i.e., the immunological microenvironment). An integrated view reflecting the complexity of both compartments might be the optimal approach in this context. PD-L1 expression emerged early as a potential predictive biomarker of response to immunotherapy. To date, most randomized clinical trials have confirmed that PD-L1 expression remains only moderately predictive, being dynamic, heterogenous, and unable to distinguish adaptive and constitutive patterns of expression and neglecting variable characteristics of the tumor immune microenvironment (Chan et al., 2019Chan T.A. Yarchoan M. Jaffee E. Swanton C. Quezada S.A. Stenzinger A. Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.Ann. Oncol. 2019; 30: 44-56Abstract Full Text Full Text PDF PubMed Scopus (490) Google Scholar). In this context, developing and harmonizing alternative and complementary predictive biomarkers, such as tumor mutational burden (TMB), tumor-infiltrating lymphocytes, expression of immune gene signatures, circulating tumor DNA or immune cells, and neoantigen prediction, shall allow refining patient selection and tailoring cancer immunotherapy strategies (Havel et al., 2019Havel J.J. Chowell D. Chan T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nat. Rev. Cancer. 2019; 19: 133-150Crossref PubMed Scopus (706) Google Scholar). In 2017, Pembrolizumab, an anti-PD-1 checkpoint inhibitor, received tissue-agnostic approval for treating solid tumors with high microsatellite instability (MSI-H) or DNA mismatch repair deficiencies (dMMR). It has been proposed that tumor mutations might represent a surrogate of the presence of neoantigen, defining higher immunogenicity. The same rationale has led to the investigation of tumor mutational burden (TMB) status as a biomarker for checkpoint inhibition. Importantly, TMB-high status, despite variable frequency across cancer types, is much more frequently encountered than MSI-H or dMMR, expanding the potential population of patients eligible for pembrolizumab. To date, most of the available data on TMB predictive ability for immunotherapy in solid tumors has come from retrospective or real-world studies. Different shreds of evidence suggest relatively consistently that tumors with higher TMB are more likely to respond to immune checkpoint blockade (Chan et al., 2019Chan T.A. Yarchoan M. Jaffee E. Swanton C. Quezada S.A. Stenzinger A. Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.Ann. Oncol. 2019; 30: 44-56Abstract Full Text Full Text PDF PubMed Scopus (490) Google Scholar), but some trials (e.g., CheckMate-227, Neoptune) failed to prospectively demonstrate improved TMB-driven efficacy—notably taking into account some confounding prognostic variables occasionally reported. Now, based on the results of the KEYNOTE-158 study, a phase 2 basket trial (Marabelle et al., 2020Marabelle A. Fakih M. Lopez J. Shah M. Shapira-Frommer R. Nakagawa K. Chung H.C. Kindler H.L. Lopez-Martin J.A. Miller Jr., W.H. et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365Abstract Full Text Full Text PDF PubMed Scopus (206) Google Scholar), pembrolizumab has received its second tissue-agnostic accelerated approval from the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors harboring high TMB (TMB-H) (≥10 mutations/megabase [mut/Mb]) that have progressed following prior treatment and have no satisfactory alternative options. In this trial including 10 cohorts, adult and also pediatric patients affected by multiple cancer types (eligible tumor types were anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small-cell lung, thyroid, and vulvar) were enrolled. The results, based on 102 patients (13%) with TMB-H (≥10 mut/Mb) compared with 688 (87%) patients with non-TMB-H status (<10 mut/Mb), showed that objective responses were observed in 29% (30/102) of TMB-H group versus 6% (43/688) in the non-TMB-H evaluable group; conversely, no significant differences were reported in terms of progression-free survival (PFS) and overall survival (OS) (Marabelle et al., 2020Marabelle A. Fakih M. Lopez J. Shah M. Shapira-Frommer R. Nakagawa K. Chung H.C. Kindler H.L. Lopez-Martin J.A. Miller Jr., W.H. et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365Abstract Full Text Full Text PDF PubMed Scopus (206) Google Scholar). Despite the strong rationale and evidence supporting the association between high TMB and ICI response, further work is still required to fully establish the utility of TMB as a clinical biomarker for solid tumors. Unlike MSI-H and dMMR status, TMB is a quantitative biomarker, requiring the definition of an appropriate threshold for each specific tumor type. To date, a wide range of cutoffs have been used to define samples with high TMB in different clinical trials (5 to ≥20), using variable techniques, material (cf. DNA from serum/plasma versus tumor tissue), and gene panels. Logically, whole-exome sequencing should remain the standard methodology to accurately determine the amount of mutations in the genome. A multiplicity of correlative studies have substituted WES with large gene panels to assess TMB, but this results in substantial misclassification rates (Budczies et al., 2019Budczies J. Allgäuer M. Litchfield K. Rempel E. Christopoulos P. Kazdal D. Endris V. Thomas M. Fröhling S. Peters S. et al.Optimizing panel-based tumor mutational burden (TMB) measurement.Ann. Oncol. 2019; 30: 1496-1506Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar). Of note, gene panels differ in their measure of the mutational burden in relation to their distinct DNA footprint, number of genes assessed, and type of mutations counted (SNV, indels, amplifications, fusions) or excluded (synonymous, drivers), and a consensus on the best approach is still lacking (Gandara et al., 2018Gandara D.R. Paul S.M. Kowanetz M. Schleifman E. Zou W. Li Y. Rittmeyer A. Fehrenbacher L. Otto G. Malboeuf C. et al.Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nat. Med. 2018; 24: 1441-1448Crossref PubMed Scopus (459) Google Scholar; Chan et al., 2019Chan T.A. Yarchoan M. Jaffee E. Swanton C. Quezada S.A. Stenzinger A. Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.Ann. Oncol. 2019; 30: 44-56Abstract Full Text Full Text PDF PubMed Scopus (490) Google Scholar; Kazdal et al., 2019Kazdal D. Endris V. Allgäuer M. Kriegsmann M. Leichsenring J. Volckmar A.L. Harms A. Kirchner M. Kriegsmann K. Neumann O. et al.Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts.J. Thorac. Oncol. 2019; 14: 1935-1947Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar). TMB scores can also vary with the purity of the tumor sample, the presence of artifact mutations in formalin-fixed paraffin-embedded samples, and even the way mutations are defined (Meléndez et al., 2018Meléndez B. Van Campenhout C. Rorive S. Remmelink M. Salmon I. D’Haene N. Methods of measurement for tumor mutational burden in tumor tissue.Transl. Lung. Cancer. Res. 2018; 7: 661-667Crossref PubMed Scopus (78) Google Scholar). While various platforms can produce substantially different results, the FDA approved the FoundationOne CDx panel used in the KEYNOTE-158 study as a companion diagnostic for pembrolizumab. Harmonization efforts, which also aim at developing tools that support calibration of different assays and comparison of assay results, are required to improve the understanding of the predictive role of TMB for ICI response related to different cancer types treated (Stenzinger et al., 2020Stenzinger A. Endris V. Budczies J. Merkelbach-Bruse S. Kazdal D. Dietmaier W. Pfarr N. Siebolts U. Hummel M. Herold S. et al.Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.J. Thorac. Oncol. 2020; 15 (Published online Feb 29, 2020): 1177-1189Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Moving forward, challenges regarding the use and understanding of TMB analysis should not necessarily be considered an impassable limit but rather a factor requiring a significant concerted effort for standardization of this practice and definition of its utility in each cancer type and a fortiori across tumor types. From this perspective, the tissue-agnostic approval of pembrolizumab in TMB-H tumors (≥10 mut/Mb), based on a compelling scientific rationale and growing clinical data, requires that the technical issues and the variance across tumor types are sufficiently communicated. Thereafter, provided TMB is appropriately evaluated, this strategy could be considered as a treatment opportunity for patients affected by a variety of rare solid cancers, particularly when no satisfactory alternative options are available. Aiming for more-accurate biomarker-driven definitions of immunogenicity, the KEYNOTE-158 trial broadens accessibility to immunotherapy based on the biological rationale of TMB as a surrogate for neoantigen expression. Specifically, it allows for pembrolizumab to be offered to patients suffering from diseases where other immunotherapy strategies or combinations are not available or where high-level evidence remains difficult to establish. Bridging this new era of biomarkers and innovative immunotherapies, using pembrolizumab in solid tumors characterized by a high TMB (≥10 mut/Mb) assessed by FoundationOne CDx assay represents a valid treatment option beyond established standards of care, offering hope for long-term benefit for some patients in many cancer types. However, cancer professionals and prescribers must be aware of all the limitations of the biomarker used, being a continuous variable missing formal prospective evaluation in any specific tumor type. Its assessment by a gene panel assay reduces its rigorous applicability globally as well as its availability. Further work around the definition of TMB is ongoing and might facilitate TMB assessment using a broader range of technologies. In the future, the predictive power of TMB might be enhanced by inferring mutational signatures directly from TMB data, which will shed light on the underlying biology (e.g., MSI, APOBEC) that shapes mutational patterns and the degree of neoantigenicity. A.P. provided consultation, attended advisory boards, or provided lectures for AstraZeneca, Agilent/Dako, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, and F Hoffmann-La Roche. A.S. provided consultation, attended advisory boards, or provided lectures for Astra Zeneca, AGCT, Bayer, Bristol-Myers Squibb, Chugai, Eli Lilly, Illumina, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, F Hoffmann-La Roche, Seattle Genetics, Takeda, and Thermo Fisher. S.P. received education grants, provided consultation, attended advisory boards, or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution).